{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:53:17Z","timestamp":1789750397739,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82104445"],"award-info":[{"award-number":["82104445"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhejiang Provincial Science and Technology Projects","award":["LGF22H160046"],"award-info":[{"award-number":["LGF22H160046"]}]},{"name":"Jinhua Municipal Science and Technology Projects","award":["2021-3-046"],"award-info":[{"award-number":["2021-3-046"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Adverse events of secondary adrenal insufficiency caused by anti-PD-1 immune agents are relatively rare in clinical practice, so in this article, we retrospectively analyzed three patients who suffered secondary adrenal cortex dysfunction caused by tislelizumab immunotherapy for Non-Small Cell Lung Cancer (NSCLC)and reviewed the literature. This rare immune-related adverse event was investigated by summarizing the clinical features of the patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We reported three NSCLC patients who suffered secondary adrenal cortex dysfunction induced by tislelizumab immunotherapy at our hospital from July 2021 to October 2023. We analyzed and summarized the clinical characteristic, laboratory examination, pathological staging, etc. We also reviewed related literature of pituitary inflammation and adrenal cortex dysfunction caused by immunotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median age of the three patients was 56 years. All the patients had a history of smoking. After receiving tislelizumab treatment (median cycle: 7), laboratory examination showed a decrease in morning cortisol and adrenocorticotropic hormone (ACTH), both were diagnosed with secondary adrenal insufficiency. Only one patient had symptoms of fatigue, vomiting, and weight loss. One of these patients also had simultaneous subclinical hypothyroidism. All three patients discontinued immunotherapy and received replacement therapy with glucocorticoids. At the last follow-up, none of the three patients restarted immunotherapy, because cortisol did not return to normal. This is similar to that of previous reports.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Based on previous reports and our three cases, when laboratory tests of NSCLC patients receiving immunotherapy showed a decrease in morning cortisol and ACTH levels, especially when clinical symptoms were obvious, the possibility of immunotherapy-related pituitary inflammation causing secondary adrenal cortex dysfunction should be considered. Prompt monitoring and hormone replacement therapy should be provided to prevent adrenal crises.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-024-03140-4","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:02:23Z","timestamp":1720443743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pituitary-adrenal axis dysfunction induced by tislelizumab immunotherapy for non-small cell lung cancer: a case series and literature review"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiayi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanrong","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yefeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"3140_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(23)00211-6","author":"J Qi","year":"2023","unstructured":"Qi J, Li M, Wang L, Hu Y, Liu W, Long Z, Zhou Z, Yin P, Zhou M. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data. Lancet Public Health. 2023. https:\/\/doi.org\/10.1016\/S2468-2667(23)00211-6.","journal-title":"Lancet Public Health"},{"key":"3140_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12197","author":"H Qiu","year":"2021","unstructured":"Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021. https:\/\/doi.org\/10.1002\/cac2.12197.","journal-title":"Cancer Commun (Lond)"},{"key":"3140_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01450-2","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021. https:\/\/doi.org\/10.1038\/s41591-021-01450-2.","journal-title":"Nat Med"},{"key":"3140_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, et al. Management of Immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385.","journal-title":"J Clin Oncol"},{"key":"3140_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0366","author":"J Wang","year":"2021","unstructured":"Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy alone as first-line treatment for Advanced squamous non-small-cell Lung Cancer: a phase 3 Randomized Clinical Trial. JAMA Oncol. 2021. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0366.","journal-title":"JAMA Oncol"},{"key":"3140_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.09.217","author":"C Zhou","year":"2023","unstructured":"Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, et al. Tislelizumab Versus Docetaxel in patients with previously treated Advanced NSCLC (RATIONALE-303): a phase 3, Open-Label, Randomized Controlled Trial. J Thorac Oncol. 2023. https:\/\/doi.org\/10.1016\/j.jtho.2022.09.217.","journal-title":"J Thorac Oncol"},{"key":"3140_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non\u2013small-cell Lung Cancer. N Engl J Med. 2015. https:\/\/doi.org\/10.1056\/NEJMoa1501824.","journal-title":"N Engl J Med"},{"key":"3140_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.039","author":"L Fehrenbacher","year":"2018","unstructured":"Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han J-Y, Gadgeel SM, Hida T, Cortinovis DL, et al. Updated efficacy analysis including secondary Population results for OAK: a Randomized Phase III Study of Atezolizumab versus Docetaxel in patients with previously treated Advanced Non-small Cell Lung Cancer. J Thorac Oncol. 2018. https:\/\/doi.org\/10.1016\/j.jtho.2018.04.039.","journal-title":"J Thorac Oncol"},{"key":"3140_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102560","author":"SM Ferrari","year":"2019","unstructured":"Ferrari SM, Fallahi P, Elia G, Ragusa F, Ruffilli I, Patrizio A, Galdiero MR, Baldini E, Ulisse S, Marone G, et al. Autoimmune endocrine dysfunctions Associated with Cancer immunotherapies. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20102560.","journal-title":"Int J Mol Sci"},{"key":"3140_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14274","author":"Y Shi","year":"2022","unstructured":"Shi Y, Fang J, Zhou C, Liu A, Wang Y, Meng Q, Ding C, Ai B, Gu Y, Yao Y, et al. Immune checkpoint inhibitor-related adverse events in lung cancer: real-world incidence and management practices of 1905 patients in China. Thorac Cancer. 2022. https:\/\/doi.org\/10.1111\/1759-7714.14274.","journal-title":"Thorac Cancer"},{"key":"3140_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12092116","author":"E Segu\u00ed","year":"2022","unstructured":"Segu\u00ed E, Zamora-Mart\u00ednez C, Barreto TD, Padrosa J, Viladot M, Marco-Hern\u00e1ndez J. Severe Immune-related adverse events: a Case Series of patients needing Hospital Admission in a Spanish Oncology Referral Center and Review of the literature. Diagnostics (Basel). 2022. https:\/\/doi.org\/10.3390\/diagnostics12092116.","journal-title":"Diagnostics (Basel)"},{"key":"3140_CR12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22070","author":"N Ganta","year":"2022","unstructured":"Ganta N, Alnabwani D, Keating S, Patel V, Bommu VJL, Dawoud R, Cheriyath P. Rare adverse events related to Nivolumab, an Immune checkpoint inhibitor: a Case Series. Cureus. 2022. https:\/\/doi.org\/10.7759\/cureus.22070.","journal-title":"Cureus"},{"key":"3140_CR13","doi-asserted-by":"publisher","DOI":"10.1159\/000507652","author":"C Salinas","year":"2020","unstructured":"Salinas C, Renner A, Rojas C, Samtani S, Burotto M. Primary adrenal insufficiency during Immune checkpoint inhibitor treatment: Case Reports and Review of the literature. Case Rep Oncol. 2020. https:\/\/doi.org\/10.1159\/000507652.","journal-title":"Case Rep Oncol"},{"key":"3140_CR14","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.09.002","author":"C Solinas","year":"2018","unstructured":"Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, Scartozzi M, Willard-Gallo K, Mariotti S, Saba L. Cancer immunotherapy-associated hypophysitis. Semin Oncol. 2018. https:\/\/doi.org\/10.1053\/j.seminoncol.2018.09.002.","journal-title":"Semin Oncol"},{"key":"3140_CR15","doi-asserted-by":"publisher","DOI":"10.13406\/j.cnki.cyxb.002758","author":"WQ Wu Yongzhong","year":"2023","unstructured":"Wu Yongzhong WQ, Pu Danlan Z, Dongling C, Bing W, Danbo C, Jianliang W, Shusen X, Yang Y, Gangyi. Chrn Jie, Zhou Qi.: Chinese expert consensus on immune checkpoint inhibitors induced emergency management of endocrine adverse reactions. J Chongqing Med Univ. 2023. https:\/\/doi.org\/10.13406\/j.cnki.cyxb.002758.","journal-title":"J Chongqing Med Univ"},{"key":"3140_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2019.1701434","author":"G Di Dalmazi","year":"2019","unstructured":"Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Rev Endocrinol Metab. 2019. https:\/\/doi.org\/10.1080\/17446651.2019.1701434.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"3140_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101370","author":"G Elia","year":"2020","unstructured":"Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo SR, Ruffilli I, Varricchi G, Fallahi P, Antonelli A. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Pract Res Clin Endocrinol Metab. 2020. https:\/\/doi.org\/10.1016\/j.beem.2019.101370.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"3140_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2017.08.019","author":"P Iglesias","year":"2018","unstructured":"Iglesias P. Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach. Eur J Intern Med. 2018. https:\/\/doi.org\/10.1016\/j.ejim.2017.08.019.","journal-title":"Eur J Intern Med"},{"key":"3140_CR19","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","author":"ES Husebye","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M, Higham CE, Lupi I, Paschou SA, Toth M, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022. https:\/\/doi.org\/10.1530\/EJE-22-0689.","journal-title":"Eur J Endocrinol"},{"key":"3140_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different Immune checkpoint inhibitor regimens: a systematic review and Meta-analysis. JAMA Oncol. 2018. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064.","journal-title":"JAMA Oncol"},{"key":"3140_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008002","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014. https:\/\/doi.org\/10.1126\/scitranslmed.3008002.","journal-title":"Sci Transl Med"},{"key":"3140_CR22","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0845","author":"F Albarel","year":"2015","unstructured":"Albarel F, Gaudy C, Castinetti F, Carr\u00e9 T, Morange I, Conte-Devolx B, Grob J-J, Brue T. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015. https:\/\/doi.org\/10.1530\/EJE-14-0845.","journal-title":"Eur J Endocrinol"},{"key":"3140_CR23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2306","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014. https:\/\/doi.org\/10.1210\/jc.2014-2306.","journal-title":"J Clin Endocrinol Metab"},{"key":"3140_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021. https:\/\/doi.org\/10.1038\/s41574-021-00484-3.","journal-title":"Nat Rev Endocrinol"},{"key":"3140_CR25","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1355337","author":"A Lammert","year":"2013","unstructured":"Lammert A, Schneider HJ, Bergmann T, Benck U, Kr\u00e4mer BK, G\u00e4rtner R, Metzner C, Sch\u00f6fl C, Berking C. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabetes. 2013. https:\/\/doi.org\/10.1055\/s-0033-1355337.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"3140_CR26","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0894","author":"SHS Pearce","year":"2021","unstructured":"Pearce SHS, Gan EH, Napier C. MANAGEMENT OF ENDOCRINE DISEASE: residual adrenal function in Addison\u2019s disease. Eur J Endocrinol. 2021. https:\/\/doi.org\/10.1530\/EJE-20-0894.","journal-title":"Eur J Endocrinol"},{"key":"3140_CR27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00229","author":"S Bhasin","year":"2018","unstructured":"Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018. https:\/\/doi.org\/10.1210\/jc.2018-00229.","journal-title":"J Clin Endocrinol Metab"},{"key":"3140_CR28","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0101","author":"F Castillero","year":"2019","unstructured":"Castillero F, Castillo-Fern\u00e1ndez O, Jim\u00e9nez-Jim\u00e9nez G, Fallas-Ram\u00edrez J, Peralta-\u00c1lvarez MP, Arrieta O. Cancer immunotherapy-associated hypophysitis. Future Oncol. 2019. https:\/\/doi.org\/10.2217\/fon-2019-0101.","journal-title":"Future Oncol"},{"key":"3140_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1289-2","author":"L Brilli","year":"2017","unstructured":"Brilli L, Danielli R, Ciuoli C, Calabr\u00f2 L, Di Giacomo AM, Cerase A, Paffetti P, Sestini F, Porcelli B, Maio M, et al. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine. 2017. https:\/\/doi.org\/10.1007\/s12020-017-1289-2.","journal-title":"Endocrine"},{"key":"3140_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.12.014","author":"E Baldini","year":"2020","unstructured":"Baldini E, Lunghi A, Cortesi E, Turci D, Signorelli D, Stati V, Melotti B, Ricciuti B, Frassoldati A, Romano G, et al. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: the Italian NSCLC expanded access program. Lung Cancer. 2020. https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.014.","journal-title":"Lung Cancer"},{"key":"3140_CR31","doi-asserted-by":"publisher","DOI":"10.1159\/000511999","author":"K Sonehara","year":"2021","unstructured":"Sonehara K, Tateishi K, Araki T, Komatsu M, Yamamoto H, Koizumi T, Hanaoka M. The role of Immune-related adverse events in prognosis and efficacy prediction for patients with Non-small Cell Lung Cancer treated with immunotherapy: a retrospective clinical analysis. Oncology. 2021. https:\/\/doi.org\/10.1159\/000511999.","journal-title":"Oncology"},{"key":"3140_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5012","author":"B Shankar","year":"2020","unstructured":"Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, et al. Multisystem Immune-related adverse events Associated with Immune Checkpoint inhibitors for treatment of Non-small Cell Lung Cancer. JAMA Oncol. 2020. https:\/\/doi.org\/10.1001\/jamaoncol.2020.5012.","journal-title":"JAMA Oncol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03140-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03140-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03140-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T08:12:44Z","timestamp":1721808764000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03140-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3140"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03140-4","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"27 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent was obtained from all participants in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed Consent for publication was obtained from all participants in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"327"}}